Skip to content
  • About us
  • Our focus
  • Team
    • Management board
    • Advisory board
  • Investors
  • Drug pipeline
  • News
  • Contact
Menu
  • About us
  • Our focus
  • Team
    • Management board
    • Advisory board
  • Investors
  • Drug pipeline
  • News
  • Contact

News

Home / Archives for May 2017

Month: May 2017

AGILeBiotics is featured in RUG’s newsletter

webmaster | Posted on 16 May 2017 |

The Newsletter from Research & Valorization of the University of Groningen (RUG) published an article about AGILeBiotics’ vision and mission.

Read moreAGILeBiotics is featured in RUG’s newsletter

Filed under: News

AGILeBiotics becomes member of Life Cooperative

webmaster | Posted on 15 May 2017 |

Life Science and Medical Technology SMEs in the Northern part of the Netherlands are uniting in the Healthy Ageing Business Cooperative in order to influence policy markers of regional governments and institutions.

Read moreAGILeBiotics becomes member of Life Cooperative

Filed under: News

Recent Posts

  • AGILeBiotics contributes to fight against future pandemic infections (e.g. COVID-19)
  • AGILeBiotics B.V. appoints new CEO Victor Schut
  • AGILeBiotics won the Investors Forum 2019 at the Dutch Life Sciences Conference
  • AGILeBiotics has been awarded the EUSMI-H2020 grant for up-scale synthesis of pre-clinical antibiotic candidate Toframicin
  • AGILeBiotics has received the Lead Development Voucher from the Netherlands Antibiotic Development Platform

Recent Comments

    Archives

    • April 2020
    • November 2019
    • October 2019
    • July 2019
    • June 2019
    • February 2019
    • October 2018
    • September 2018
    • August 2018
    • April 2018
    • February 2018
    • November 2017
    • October 2017
    • August 2017
    • June 2017
    • May 2017
    • April 2017
    • March 2017
    • February 2017

    Categories

    • featured
    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    About

    AGILeBiotics B.V. is a pharmaceutical company focusing on the development of novel antibiotics for the treatment of multi-drug resistant infections

    Linkedin

    Latest news

    AGILeBiotics contributes to fight against future pandemic infections (e.g. COVID-19)

    7 April 2020

    AGILeBiotics B.V. appoints new CEO Victor Schut

    6 April 2020

    AGILeBiotics won the Investors Forum 2019 at the Dutch Life Sciences Conference

    28 November 2019

    AGILeBiotics has been awarded the EUSMI-H2020 grant for up-scale synthesis of pre-clinical antibiotic candidate Toframicin

    14 October 2019

    Copyright © 2018 AGILeBiotics | All Rights Reserved. | Webdevelopment Skitter